Voluntis and AstraZeneca win prestigious Prix Galien MedStartUp award for 'Best Patient Engagement Techologies' for eCO

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a company specialized in digital therapeutics, and AstraZeneca (NYSE: AZN) announced that they have been awarded the 2018 Prix Galien – MedS­tartUp Award for Best Patient Engagement Technology for eCO. The award recognizes outstanding partnerships between French and North American entities to improve health care. It was presented at a ceremony in New York City on October 25, 2018.

“We are honored to receive this prestigious award, which recognizes eCO as a significant achievement in improving patients’ lives. It is also an acknowledgement of the strength of our partnership with AstraZeneca and the National Cancer Institute. We have been delighted to work with them in developing eCO as we bring our respective expertise and passion for patients. As they say at Prix Galien, ‘Actors win Oscars, innovators win the Prix Galien.’” 

Pierre Leurent, CEO of Voluntis

eCO is a companion digital therapeutic developed by Voluntis, in partnership with AstraZeneca and the National Cancer Institute, for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of Cediranib plus Olaparib. It aims to help these women manage symptoms sometimes associated with their treatment in collaboration with their care teams via a patient app and clinician web portal. In a feasibility study, published in the Journal of Clinical Oncology (JCO®) Clinical Cancer Informatics, patients had statistically significant, positive responses to the use of the eCO application. Patients indicated that using eCO made them feel more involved in their care and better connected to their healthcare team.